A股異動丨長春高新(000661.SZ)反彈約4% 部分股東及高管擬以3000萬-5000萬增持公司股份
格隆匯8月9日丨上週捱了一個跌停板後,千億白馬股——生長激素龍頭企業長春高新(000661.SZ)的股東似乎有點坐不住了。8月6日晚間,長春高新公吿,第二大股東金磊,以及公司現任董事馬驥、姜雲濤、王志剛、監事趙樹平、高級管理人員李秀峯、朱興功、張德申,計劃6個月內以自有或自籌資金增持公司股份,增持金額合計為3000萬元至5000萬元。長春高新(000661.SZ)今日反彈近4%,報288.52元,總市值1168億元,不過其股價今年累計跌幅仍達到36%。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.